Mammalian stable expression of biotherapeutics

Methods in Molecular Biology

Volumn 899, Issue , 2012, Pages 227-238

  Jostock, Thomas ^a   Knopf, Hans Peter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibody; Biomanufacturing; Cell line development; CHO; Stable expression

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CHO CELL; CYTOLOGY; GENE VECTOR; GENETIC PROCEDURES; GENETIC TRANSFECTION; GENETICS; HAMSTER; HIGH THROUGHPUT SCREENING; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY;

ANIMALS; ANTIBODIES; CHO CELLS; CRICETINAE; GENETIC TECHNIQUES; GENETIC VECTORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOGLOBULIN G; RECOMBINANT PROTEINS; TRANSFECTION;

MAMMALIA;

EID: 84864123923     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-921-1_15     Document Type: Article

References (51)

1. Takeuchi M, Kobata A (1991) Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1:337-346
2. Jefferis R (2007) Antibody therapeutics: Isotype and glycoform selection. Expert Opin Biol Ther 7:1401-1413
3. Wurm FM (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393-1398
4. Jostock T (2011) Expression of antibody in mammalian cells. In: Al-Rubeai M (ed) Cell Engineering. Springer Science and Business Media B.V., Dordrecht
5. Puck TT (1958) Genetics of somatic mammalian cells. J Exp Med 108:945-955
6. Urlaub G, Chasin LA (1980) Isolation of Chinese hamster cell mutants de fi cient in dihydrofolate reductase activity. Proc Natl Acad Sci U S A 77:4216-4220
7. Urlaub G, Kas E, Carothers AM, Chasin LA (1983) Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell 33:405-412
8. Fussenegger M, Bailey JE, Hauser H, Mueller PP (1999) Genetic optimization of recombinant glycoprotein production by mammalian cells. Trends Biotechnol 17:35-42
9. Dinnis DM, James DC (2005) Engineering mammalian cell factories for improved recombinant monoclonal antibody production: Lessons from nature? Biotechnol Bioeng 91:180-189
10. Florin L, Pegel A, Becker E, Hausser A, Olayioye MA, Kaufmann H (2009) Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells. J Biotechnol 141:84-90
11. Yamane-Ohnuki N, Kinoshita S, Inoue- Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, Shitara K, Satoh M (2004) Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody- dependent cellular cytotoxicity. Biotechnol Bioeng 87:614-622
12. Yamane-Ohnuki N, Yamano K, Satoh M (2008) Biallelic gene knockouts in Chinese hamster ovary cells. Methods Mol Biol 435:1-16
13. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176-180
14. Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671-685
15. Durocher Y, Butler M (2009) Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol 20:700-707
16. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74
17. Shaw G, Morse S, Ararat M, Graham FL (2002) Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J 16:869-871
18. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, van der Helm E, Smits S, Schouten J, Brouwer K, Lagerwerf F, van Berkel P, Opstelten DJ, Logtenberg T, Bout A (2003) High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 19:163-168
19. Rose T, Winkler K, Brundke E, Jordan I, Sandig V (2005) Alternative strategies and new cell lines for high-level production of biopharmaceuticals. In: Knäblein J (ed) Modern biopharmaceuticals, Wiley-VCH, pp 761-777
20. Olivier S, Jacoby M, Brillon C, Bouletreau S, Mollet T, Nerriere O, Angel A, Danet S, Souttou B, Guehenneux F, Gauthier L, Berthome M, Vie H, Beltraminelli N, Mehtali M (2010) EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity. MAbs 2:405-415
21. Weber W, Fussenegger M (2004) Inducible gene expression in mammalian cells and mice. Methods Mol Biol 267:451-466
22. Kalwy S, Rance J, Young R (2006) Toward more Efficient protein expression: Keep the message simple. Mol Biotechnol 34:151-156
23. Schlatter S, Stans fi eld SH, Dinnis DM, Racher AJ, Birch JR, James DC (2005) On the optimal ratio of heavy to light chain genes for Efficient recombinant antibody production by CHO cells. Biotechnol Prog 21:122-133
24. Jostock T, Vanhove M, Brepoels E, Van Gool R, Daukandt M, Wehnert A, Van Hegelsom R, Drans fi eld D, Sexton D, Devlin M, Ley A, Hoogenboom H, Mullberg J (2004) Rapid generation of functional human IgG antibodies derived from Fab-On-phage display libraries. J Immunol Methods 289:65-80
25. Li J, Menzel C, Meier D, Zhang C, Dubel S, Jostock T (2007) A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. J Immunol Methods 318:113-124
26. Li J, Zhang C, Jostock T, Dubel S (2007) Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Eng Des Sel 20: 491-496
27. Borman AM, Deliat FG, Kean KM (1994) Sequences within the poliovirus internal ribosome entry segment control viral RNA synthesis. EMBO J 13:3149-3157
28. Fang J, Qian JJ, Yi S, Harding TC, Tu GH, VanRoey M, Jooss K (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 23:584-590
29. Jostock T, Dragic Z, Fang J, Jooss K, Wilms B, Knopf HP (2010) Combination of the 2A/ furin technology with an animal component free cell line development platform process. Appl Microbiol Biotechnol 87:1517-1524
30. Oumard A, Qiao J, Jostock T, Li J, Bode J (2006) Recommended method for chromosome exploitation: RMCE-based cassetteexchange systems in animal cell biotechnology. Cytotechnology 50:93-108
31. Bode J, Schlake T, Iber M, Schubeler D, Seibler J, Snezhkov E, Nikolaev L (2000) The transgeneticist's toolbox: Novel methods for the targeted modi fi cation of eukaryotic genomes. Biol Chem 381:801-813
32. O'Gorman S, Fox DT, Wahl GM (1991) Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science 251:1351-1355
33. Fukushige S, Sauer B (1992) Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells. Proc Natl Acad Sci U S A 89:7905-7909
34. Arnould S, Delenda C, Grizot S, Desseaux C, Paques F, Silva GH, Smith J (2010) The I-CreI meganuclease and its engineered derivatives: Applications from cell modi fi cation to gene therapy. Protein Eng Des Sel 24:27-31
35. Porteus MH, Carroll D (2005) Gene targeting using zinc fi nger nucleases. Nat Biotechnol 23: 967-973
36. Kennard ML, Goosney DL, Monteith D, Zhang L, Moffat M, Fischer D, Mott J (2009) The generation of stable, high MAb expressing CHO cell lines based on the Artificial chromosome expression (ACE) technology. Biotechnol Bioeng 104:540-553
37. Cacciatore JJ, Chasin LA, Leonard EF (2010) Gene ampli fi cation and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnol Adv 28: 673-681
38. Mott J (2011) Cell line development and engineering conference, Munich
39. Jostock T, Knopf H-P, Wilms B, Drori S, Assaraf YGA (2010) Antibody development and production conference. IBCLifeScience, Carlsbad, CA
40. Browne SM, Al-Rubeai M (2007) Selection methods for high-producing mammalian cell lines. Trends Biotechnol 25:425-432
41. Carroll S, Al-Rubeai M (2004) The selection of high-producing cell lines using flow cytometry and cell sorting. Expert Opin Biol Ther 4:1821-1829
42. Manz R, Assenmacher M, P fl uger E, Miltenyi S, Radbruch A (1995) Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface af fi nity matrix. Proc Natl Acad Sci U S A 92:1921-1925
43. Holmes P, Al-Rubeai M (1999) Improved cell line development by a high throughput af fi nity capture surface display technique to select for high secretors. J Immunol Methods 230: 141-147
44. Borth N, Zeyda M, Kunert R, Katinger H (2000) Efficient selection of high-producing subclones during gene ampli fi cation of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. Biotechnol Bioeng 71:266-273
45. Brezinsky SC, Chiang GG, Szilvasi A, Mohan S, Shapiro RI, MacLean A, Sisk W, Thill G (2003) A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J Immunol Methods 277: 141-155
46. DeMaria CT, Cairns V, Schwarz C, Zhang J, Guerin M, Zuena E, Estes S, Karey KP (2007) Accelerated clone selection for recombinant CHO CELLS using a FACS-based highthroughput screen. Biotechnol Prog 23: 465-472
47. Sleiman RJ, Gray PP, McCall MN, Codamo J, Sunstrom NA (2008) Accelerated cell line development using two-color fluorescence activated cell sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng 99:578-587
48. Powell KT, Weaver JC (1990) Gel microdroplets and flow cytometry: Rapid determination of antibody secretion by individual cells within a cell population. Biotechnology (N Y) 8: 333-337
49. Kenney JS, Gray F, Ancel MH, Dunne JF (1995) Production of monoclonal antibodies using a secretion capture report web. Biotechnology (N Y) 13:787-790
50. Porter AJ, Dickson AJ, Racher AJ (2010) Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: Realizing the potential in bioreactors. Biotechnol Prog 26: 1446-1454
51. Porter AJ, Racher AJ, Preziosi R, Dickson AJ (2010) Strategies for selecting recombinant CHO cell lines for cGMP manufacturing: Improving the ef fi ciency of cell line generation. Biotechnol Prog 26:1455-1464